| Name | Title | Contact Details |
|---|
Gen-Diagnostics Incorporated is a San Juan Capistrano, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
WellCare Health Plans (NYSE: WCG) is a FORTUNE 500 company based in Tampa, Fla., employing more than 5,000 associates nationwide. WellCare has developed a full complement of expertise in the three major areas of government-sponsored health care…. Medicaid, Medicare Advantage and Medicare Prescription Drug Plans. Leveraging these for our members` benefit is a key part of the value we bring to our members. WellCare has a focus on those members who are dually eligible for both Medicaid and Medicare. This is an area of specialization that many other health plans simply do not have. We are committed to continually improving the quality of care and service that we provide to our members. We help our members access the right care at the right time in the appropriate setting through coordinated care teams and community partnerships. And we`re focused on government customers and use a disciplined approach to ensuring a competitive cost structure.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
John J. Morgan and David R. White founded MorganWhiteGroup, Inc. in 1987. The business started out primarily focusing on payroll deduction of supplemental insurance products, and has grown into what is today, a holding company made up of 6 wholly owned subsidiaries. The MorganWhiteGroup of companies now includes: Two sales agencies, MWG Employer Services and MWG Senior Healthcare, two third-party administrators (TPAs), MorganWhite Administrators, Inc. and MorganWhite Administrators International, a marketing agency, MWG Marketing, and a Reinsurance Intermediary, MWG Reinsurance, Inc. Our success since 1987 has been achieved by delivering insurance products to the marketplace that cannot be found anywhere else. Our company's guiding principal has been to find a market that is either under-served or not served at all and design a product to fit that market. At MorganWhiteGroup, we look forward to the challenge of solving customers’ medical, dental and vision insurance needs today, and in the future. We are committed to making the investment in technology, equipment, and personnel to provide our customers with the latest, most up to date tools available, to solve their insurance needs.
ReVision Optics®, Inc., (RVO) is a privately held corporation headquartered in Southern California, USA. RVO`s main focus is developing unique optical solutions for the treatment of presbyopia. Fueled by a belief that no one should ever have to hold a menu out at arm`s length, the company developed the Raindrop® Near Vision Corneal Inlay, a unique patented refractive surgery solution. This inlay is designed to improve the near vision that has been lost by the eye`s natural aging process, called presbyopia. The Company is actively pursuing regulatory approvals and market opportunities for Raindrop® worldwide, and is committed to ridding the world of reading glasses, one satisfied patient at a time.